Even though the status of CARMA1 and other oncogenes was not analyzed in the respective patient samples, high β-catenin amounts are more frequent than CARMA1 mutations and may be in the range of patients that carry either CARMA1 or CD79B mutations (~30% of all ABC DLBCL).3, 7, 9 Clearly, further analyses will be required to correlate the mutation status and β-catenin levels in DLBCL subtypes. This evidence concerns the gene CD79B and diffuse large B-cell lymphoma.